|
| Human DSG3 (HLA-A*01:01) Protein (LTP10084) |
|
| LTP10084 |
|
| 100ug |
|
|
$406 In stock |
| DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. |
| Recombinant Human DSG3 (HLA-A*01:01) Protein is expressed from Expi293 with His tag and Avi Tag at the C-terminal. It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide.. |
|
| DSG3 (HLA-A*01:01) |
|
| Human |
|
| Q5SUL5(HLA-A*01:01)&P61769(B2M)&YTDNWLAVY |
|
| Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M)and YTDNWLAVY peptide. |
|
| The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on the Tris-Bis PAGE result. |
|
| 0 |
|
| C-His-Avi |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
